We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Aripiprazole, Abilify Maintena Collaborative Clinical Protocol

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02717130
Recruitment Status : Terminated (The study was terminated due to lack of enrollment.)
First Posted : March 23, 2016
Results First Posted : April 13, 2020
Last Update Posted : April 13, 2020
Washington University School of Medicine
University of Missouri-Columbia
University of Missouri, Kansas City
Burrell Behavioral Health
Information provided by (Responsible Party):
Florida Atlantic University

Brief Summary:
An Open-label, Multi-center, Longitudinal, Within-subject Comparison Study to Evaluate the Effects of Aripiprazole Once Monthly in Subjects with Schizophrenia on 30-, 90-, and 180- day Re-hospitalization Rates Following Hospital Discharge Compared with Retrospective Re-hospitalization Rates while on Oral Antipsychotic Medication.

Condition or disease Intervention/treatment Phase
Schizophrenia Drug: Aripiprazole Not Applicable

Show Show detailed description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 9 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Aripiprazole, Abilify Maintena Collaborative Clinical Protocol
Actual Study Start Date : June 8, 2016
Actual Primary Completion Date : May 25, 2017
Actual Study Completion Date : May 25, 2017

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Schizophrenia

Arm Intervention/treatment
Experimental: Aripiprazole (Abilify Maintena)
Aripiprazole once monthly (300-400 mg for entire study duration) plus 14 days oral antipsychotic medication (first injection only) (dosage according to package inserts). After the 14 day oral lead-in, after the first injection of aripiprazole once monthly, only oral aripiprazole will be allowed as a rescue medication.
Drug: Aripiprazole

Primary Outcome Measures :
  1. Assessment of Hospital Re-admission in a 30 Day Time Frame [ Time Frame: 30 days ]
    Psychiatric re-hospitalization were planning to be assessed using hospital admission records. Study stopped due to lack of enrollment.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Are able to provide written informed consent.
  • Are male and female subjects 18 to 65 years of age, inclusive, at time of informed consent
  • Have a current diagnosis of schizophrenia as defined by DSM-5 criteria and a history of the illness for at least 6 months prior to screening from a reliable source (e.g., subject, family member, friend, caregiver, healthcare provider, or medical records)
  • Present at one of the selected inpatient units with acute psychotic symptoms for hospitalization at study entry
  • Have a clinically indicated need for a change in current antipsychotic therapy
  • Are on Medicaid with searchable claims data
  • Have at least one inpatient psychiatric hospitalization or psychiatric ED visit within the 6 months prior to screening
  • Have been previously prescribed oral antipsychotic treatment for the 6 consecutive months prior to screening
  • Have a history of response to antipsychotic treatment, with no history of clozapine treatment
  • Are able to understand the nature of the study and follow protocol requirements, including the prescribed dosage regimens, tablet ingestion, aripiprazole once monthly injection, and discontinuation of prohibited concomitant medications
  • Are able to read and understand the written word in order to complete subject-reported outcomes measures
  • Are willing to accept a monthly injection
  • Are male and female subjects who are surgically sterile (i.e., have undergone orchiectomy or hysterectomy, respectively); female subjects who have been postmenopausal for at least 12 consecutive months; or male and female subjects who agree to use an approved form of birth control during study participation

Exclusion Criteria:

  • Has a current DSM-5 diagnosis other than schizophrenia, including schizophreniform disorder, schizoaffective disorder, major depressive disorder, bipolar disorder, delirium, dementia, amnestic or other cognitive disorders. Also excluded are subjects with borderline, paranoid, histrionic, schizotypal, schizoid, or antisocial personality disorder.
  • Prisoners or subjects who are involuntarily incarcerated, or have been incarcerated in the past 7 months for any reason
  • Require potent cytochrome P450 (CYP)2D or CYP3A4 inhibitors or CYP3A4 inducers
  • Are allergic, intolerant, or unresponsive to prior treatment with aripiprazole or other quinolinones or has a history of hypersensitivity to antipsychotic agents
  • Have received electroconvulsive therapy within the 6 months prior to screening
  • Have a history of neuroleptic malignant syndrome or clinically significant tardive dyskinesia as assessed by the investigator
  • Have current diagnosis of diabetes or known fasting triglyceride levels consistent with risk for pancreatitis
  • Meets DSM-5 criteria for current substance use disorder within 3 months prior to screening
  • Received treatment with long-acting injectable antipsychotics (e.g., haloperidol decanoate, fluphenazine decanoate, risperidone long-acting injection [Risperdal Consta®], paliperidone palmitate extended-release injectable suspension [Invega® Sustenna®], olanzapine for extended-release injectable suspension [Zyprexa® Relprevv™]), in which the last dose was within 7 months prior to screening
  • Have a significant risk of committing suicide based on history, routine psychiatric status examination, investigator's judgment, or who have an answer of "yes" on Question 4 or Question 5 within the last 30 days on the baseline version of the C-SSRS
  • Have a history or evidence of a medical condition that would expose them to an undue risk of a significant AE or interfere with assessments of safety or efficacy during the course of the study, including but not limited to hepatic, renal, respiratory, cardiovascular, endocrine, neurologic, hematologic, or immunologic disease as determined by the clinical judgment of the investigator
  • Have results from one or more of the following laboratory test, vital sign, and ECG tests at screening that are exclusionary (laboratory testing and ECGs will be performed locally): Platelets ≤ 75,000/mm3; Hemoglobin ≤ 9 g/dL; Fasting blood glucose > 126 mg/dL or HbA1c > 7.0%; Fasting triglyceride > 500 mg/dL; Neutrophils, absolute ≤ 1000/mm3; Aspartate transaminase (AST) > 3x ULN; Alanine transaminase (ALT) > 3x ULN; Creatinine ≥ 2 mg/dL; Diastolic blood pressure > 105 mmHg; QTc > 475 msec on either the QTcB (Bazett) or QTcF (Fridericia) corrections on ECG, confirmed by a second tracing; Any other abnormal laboratory tests, vital sign results, or ECG findings that, in the judgment of the investigator, are medically significant and would affect the safety of the subject or the interpretation of the study results. Abnormal results for laboratory parameters or vital signs should be repeated to ensure reproducibility of the abnormality before excluding a subject based on the criteria noted above.
  • Have been previously enrolled in an aripiprazole once monthly clinical study
  • Have participated in any clinical study with an investigational agent within the past 30 days
  • Are pregnant or lactating

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02717130

Layout table for location information
United States, Missouri
University of Missouri
Columbia, Missouri, United States, 65211
University of Missouri
Kansas City, Missouri, United States, 64108
Washington University
Saint Louis, Missouri, United States, 63110
Burrell Behavioral Health
Springfield, Missouri, United States, 65804
Sponsors and Collaborators
Florida Atlantic University
Washington University School of Medicine
University of Missouri-Columbia
University of Missouri, Kansas City
Burrell Behavioral Health
Layout table for investigator information
Principal Investigator: John Newcomer, MD Florida Atlantic University
Principal Investigator: Ginger Nicol, MD Washington University School of Medicine
  Study Documents (Full-Text)

Documents provided by Florida Atlantic University:
Additional Information:

Layout table for additonal information
Responsible Party: Florida Atlantic University
ClinicalTrials.gov Identifier: NCT02717130    
Other Study ID Numbers: 031-104-0014
First Posted: March 23, 2016    Key Record Dates
Results First Posted: April 13, 2020
Last Update Posted: April 13, 2020
Last Verified: April 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Schizophrenia Spectrum and Other Psychotic Disorders
Mental Disorders
Antidepressive Agents
Psychotropic Drugs
Antipsychotic Agents
Tranquilizing Agents
Central Nervous System Depressants
Physiological Effects of Drugs
Dopamine Agonists
Dopamine Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Serotonin 5-HT1 Receptor Agonists
Serotonin Receptor Agonists
Serotonin Agents
Serotonin 5-HT2 Receptor Antagonists
Serotonin Antagonists
Dopamine D2 Receptor Antagonists
Dopamine Antagonists